Eltrombopag Teva GmbH
Thrombopoietin receptor agonist for thrombocytopenia
Eltrombopag Teva GmbH is a prescription thrombopoietin receptor agonist (TPO-RA) that stimulates the bone marrow to produce more platelets. It is used to treat chronic immune thrombocytopenia (ITP) in adults who have not responded adequately to other treatments, thrombocytopenia in adults with chronic hepatitis C to enable antiviral therapy, and severe aplastic anemia in adults with insufficient response to immunosuppressive therapy. This guide covers dosage, side effects, drug interactions, and important safety information based on international clinical guidelines.
Quick Facts
Key Takeaways
- Eltrombopag stimulates platelet production by activating the thrombopoietin receptor on megakaryocytes in the bone marrow, and is approved for chronic ITP, hepatitis C-associated thrombocytopenia, and severe aplastic anemia.
- Liver function must be monitored regularly before and during treatment due to the risk of hepatotoxicity; treatment should be discontinued if ALT levels rise significantly.
- The tablet must be taken on an empty stomach — at least 2 hours before or 4 hours after food, dairy, or mineral supplements — as polyvalent cations severely reduce absorption.
- Platelet counts should be monitored weekly during dose adjustment and at least monthly once stable; the goal is not to normalize platelet counts but to reduce bleeding risk.
- Stopping eltrombopag abruptly may cause platelet counts to drop below pre-treatment levels, increasing bleeding risk for up to 2 weeks after discontinuation.
What Is Eltrombopag Teva GmbH and What Is It Used For?
Eltrombopag Teva GmbH contains the active substance eltrombopag olamine, a small-molecule, non-peptide thrombopoietin receptor agonist. Unlike endogenous thrombopoietin (TPO), which binds to the extracellular domain of the TPO receptor (also known as c-Mpl), eltrombopag interacts with the transmembrane domain of the receptor. This unique binding site means eltrombopag works additively with endogenous TPO rather than competing with it, triggering intracellular signaling cascades — primarily the JAK-STAT and MAPK pathways — that promote the proliferation and differentiation of megakaryocyte progenitor cells into mature, platelet-producing megakaryocytes.
The medicine is approved for three primary indications. First, it is used in adults with chronic immune thrombocytopenia (ITP) who are splenectomized and have an insufficient response to splenectomy, or who are non-splenectomized and have an insufficient response to corticosteroids, immunoglobulins, or other standard first-line therapies. ITP is an autoimmune disorder characterized by the destruction of platelets by autoantibodies and impaired platelet production, leading to dangerously low platelet counts and increased bleeding risk. Eltrombopag addresses the production deficit by stimulating new platelet formation.
Second, eltrombopag is indicated for adults with chronic hepatitis C virus (HCV) infection and thrombocytopenia, where the low platelet count prevents the initiation or continuation of interferon-based antiviral therapy. Thrombocytopenia is common in patients with chronic HCV infection due to reduced TPO production by the liver, portal hypertension-related splenic sequestration, and bone marrow suppression. By raising platelet counts, eltrombopag enables these patients to receive effective antiviral treatment with optimal dosing.
Third, eltrombopag is approved for adults with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy. SAA is a rare bone marrow failure syndrome resulting in pancytopenia. In this setting, eltrombopag has been shown not only to increase platelet counts but also to promote multilineage hematopoietic recovery, suggesting a broader effect on hematopoietic stem cells. The landmark NHLBI clinical trials demonstrated that adding eltrombopag to standard immunosuppressive therapy with horse antithymocyte globulin and cyclosporine significantly improved overall response rates in treatment-naive SAA patients.
Eltrombopag Teva GmbH is a generic formulation manufactured by Teva GmbH. It is bioequivalent to the originator product and is available as 25 mg film-coated tablets for oral administration. The medicine is listed on the WHO Model List of Essential Medicines, reflecting its importance in global healthcare for the treatment of thrombocytopenic conditions.
What Should You Know Before Taking Eltrombopag Teva GmbH?
Contraindications
You should not take Eltrombopag Teva GmbH if you are allergic to eltrombopag olamine or any of the other ingredients in the tablet. Hypersensitivity reactions, although rare, have been reported and can include skin rash, pruritus, and in very rare cases, anaphylactic-type reactions. If you have previously experienced an allergic reaction to eltrombopag or any component of the formulation, you must inform your healthcare provider before starting treatment.
Warnings and Precautions
Eltrombopag can cause serious liver injury (hepatotoxicity). Liver function tests (ALT, AST, bilirubin) must be performed before starting treatment, every two weeks during dose adjustment, and monthly during stable therapy. If bilirubin is elevated or ALT rises above 3 times the upper limit of normal and is progressive, persists for 4 or more weeks, is accompanied by increased direct bilirubin, or is accompanied by clinical symptoms of liver injury, discontinue eltrombopag.
Thrombotic and thromboembolic risk: Eltrombopag increases platelet production, which may raise the risk of thrombotic or thromboembolic complications, including deep vein thrombosis (DVT), pulmonary embolism (PE), transient ischemic attacks (TIA), myocardial infarction, and stroke. This risk may be particularly elevated in patients with known risk factors for thromboembolism, such as Factor V Leiden mutation, antithrombin III deficiency, antiphospholipid syndrome, immobilization, advanced age, malignancy, or use of oral contraceptives. Patients with chronic liver disease and portal hypertension are at particular risk for portal vein thrombosis. The dose should be adjusted to maintain the lowest platelet count sufficient to reduce bleeding risk, and should not be used to normalize platelet counts.
Bone marrow reticulin formation: Eltrombopag may increase reticulin fiber deposition in the bone marrow. The clinical significance of bone marrow reticulin formation is not fully established, but progression to collagen fibrosis has been reported rarely. A peripheral blood smear should be examined at baseline and monthly during treatment to check for abnormal cell morphology (e.g., teardrop cells, nucleated red blood cells) that may indicate developing myelofibrosis. If morphological abnormalities are detected, bone marrow biopsy should be considered.
Worsening thrombocytopenia after discontinuation: Following discontinuation of eltrombopag, platelet counts may drop below pre-treatment baseline levels for approximately 2 weeks, increasing the risk of bleeding. Platelet counts should be monitored weekly for at least 4 weeks after stopping treatment. Some patients may require additional medical management to prevent clinically significant bleeding during this period.
Loss of response: A clinically important loss of platelet response or failure to maintain a platelet response at a well-tolerated dose may indicate new bone marrow pathology, including increased reticulin or myelofibrosis. A peripheral blood smear and complete blood count with differential should be assessed, and bone marrow biopsy considered if abnormalities are found.
Cataracts: In clinical trials, cataracts developed or worsened in patients treated with eltrombopag, particularly in rodent studies. Although a causal relationship has not been firmly established in humans, ophthalmic examinations are recommended before starting treatment and regularly during therapy.
Pregnancy and Breastfeeding
Pregnancy: There are limited data on the use of eltrombopag in pregnant women. Animal studies have shown reproductive toxicity including reduced fetal weight, increased incidence of cervical ribs, and embryolethality at doses associated with maternal toxicity. Eltrombopag Teva GmbH should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
Breastfeeding: It is unknown whether eltrombopag or its metabolites are excreted in human breast milk. A risk to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. In animal studies, eltrombopag was detected in breast milk.
How Does Eltrombopag Teva GmbH Interact with Other Drugs?
Eltrombopag undergoes extensive metabolism primarily through CYP1A2 and CYP2C8 oxidation and UGT1A1 and UGT1A3 glucuronidation. It is also a substrate and inhibitor of key drug transporters including OATP1B1 (organic anion transporting polypeptide 1B1) and BCRP (breast cancer resistance protein). These metabolic and transport pathways form the basis for most clinically significant drug interactions.
Chelation with polyvalent cations represents the most clinically important interaction. Eltrombopag chelates with polyvalent cations such as aluminium, calcium, iron, magnesium, selenium, and zinc, forming insoluble complexes that are poorly absorbed from the gastrointestinal tract. Plasma exposure of eltrombopag can be reduced by up to 70% when taken with calcium-containing products. This means that antacids, dairy products, mineral supplements, and calcium-fortified foods must be separated from eltrombopag dosing by appropriate time intervals.
Major Interactions
| Interacting Drug | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Antacids (Al, Ca, Mg) | Chelation of polyvalent cations | Up to 70% reduction in eltrombopag absorption | Take eltrombopag at least 2 hours before or 4 hours after antacids |
| Iron supplements | Chelation with iron ions | Significant reduction in eltrombopag bioavailability | Separate by at least 4 hours |
| Rosuvastatin | OATP1B1 and BCRP inhibition | 55% increase in rosuvastatin Cmax; increased risk of myopathy | Start rosuvastatin at lowest dose; monitor for signs of myopathy |
| Methotrexate | BCRP and OATP1B1 inhibition | Increased methotrexate exposure and potential toxicity | Monitor methotrexate levels and adjust dose if needed |
| Cyclosporine | OATP1B1 inhibition by cyclosporine | Potential reduction in eltrombopag hepatic uptake | Monitor platelet count and adjust dose accordingly |
| Lopinavir/ritonavir | OATP1B1 inhibition and CYP1A2/UGT1A1 modulation | Reduced eltrombopag concentration by ~17% | Monitor platelet response closely |
Minor Interactions
Dairy products and calcium-fortified foods: Calcium in dairy products (milk, cheese, yogurt) and fortified foods (orange juice, cereals) chelates eltrombopag and reduces absorption. Take eltrombopag on an empty stomach at least 2 hours before or 4 hours after these products.
Other statins: While the most significant interaction is with rosuvastatin (a BCRP substrate), other statins metabolized by different pathways (e.g., atorvastatin via CYP3A4) have not shown clinically meaningful interactions. However, monitoring is recommended when initiating or changing statin therapy.
Warfarin and other anticoagulants: Although no direct pharmacokinetic interaction has been demonstrated between eltrombopag and warfarin, both drugs are highly protein-bound (>99%). Co-administration with anticoagulants or antiplatelet agents should involve careful monitoring, as changes in platelet count may affect bleeding or clotting risk.
CYP enzyme inducers: Strong inducers of CYP1A2 (e.g., tobacco smoke, omeprazole at high doses) or CYP2C8 (e.g., rifampicin) may reduce eltrombopag plasma concentrations. Although no specific dose adjustment recommendations exist, monitoring of platelet response is advised when these inducers are started or discontinued.
What Is the Correct Dosage of Eltrombopag Teva GmbH?
Eltrombopag dosing is individualized based on platelet count response. The goal of therapy is to achieve and maintain a platelet count at the lowest level sufficient to reduce bleeding risk (generally ≥50 × 109/L), not to normalize platelet counts. Treatment should be initiated and supervised by a physician experienced in the management of hematological conditions.
Adults — Chronic Immune Thrombocytopenia (ITP)
Standard Starting Dose
50 mg once daily for most adult patients. For patients of East Asian ancestry (Chinese, Japanese, Korean, Taiwanese), the recommended starting dose is 25 mg once daily due to higher eltrombopag exposure observed in pharmacokinetic studies in these populations.
Dose Adjustment
Adjust the dose in increments of 25 mg based on platelet count response. Wait at least 2 weeks between dose adjustments. If the platelet count is <50 × 109/L after 2 weeks, increase by 25 mg (maximum 75 mg/day). If the platelet count is between 200-400 × 109/L, decrease by 25 mg. If the platelet count exceeds 400 × 109/L, stop treatment and resume at a reduced dose once platelets fall below 150 × 109/L.
Adults — Hepatitis C-Associated Thrombocytopenia
Starting Dose
25 mg once daily. Adjust in increments of 25 mg every 2 weeks to achieve a platelet count sufficient to initiate antiviral therapy (target usually ≥75 × 109/L). Maximum dose: 100 mg/day.
Adults — Severe Aplastic Anemia (SAA)
Starting Dose
50 mg once daily (25 mg for East Asian patients). Dose may be increased to 75 mg after 2 weeks, then to 150 mg maximum after a further 2 weeks if platelet response is insufficient. The dose for SAA may be higher than for ITP because the bone marrow failure requires more aggressive stimulation of residual megakaryocyte progenitors.
Children and Adolescents
The use of Eltrombopag Teva GmbH in children and adolescents under 18 years has not been established for this specific generic formulation. The originator product (eltrombopag) is approved in some jurisdictions for children aged 1 year and above with chronic ITP. In pediatric ITP, the starting dose is typically 25 mg once daily for ages 6-17, and weight-based dosing for ages 1-5. Pediatric dosing should be managed by a specialist hematologist. Consult local prescribing information for age-specific guidance.
Elderly Patients
No specific dose adjustment is required for elderly patients (≥65 years) based solely on age. However, elderly patients are more likely to have reduced hepatic and renal function, multiple comorbidities, and concomitant medications that may affect eltrombopag pharmacokinetics or increase the risk of thromboembolic events. Closer monitoring and more conservative dose titration are recommended. Clinical trial data included patients up to 85 years of age, and the safety and efficacy profile was generally consistent across age groups, though the number of patients ≥75 years was limited.
Missed Dose
If you miss a dose, take it as soon as you remember on the same day. Do not take two doses on the same day to make up for a missed dose. Simply skip the missed dose and continue with your normal schedule the next day. If you frequently miss doses, your platelet count may decrease, increasing bleeding risk. Set a daily reminder to help maintain consistent dosing.
Overdose
In case of overdose, platelet counts may rise excessively, increasing the risk of thrombotic or thromboembolic complications. Seek immediate medical attention. There is no specific antidote for eltrombopag. Monitor platelet count closely and initiate supportive measures. Hemodialysis is not expected to enhance elimination, as eltrombopag is highly protein-bound (>99%). In clinical trials, doses up to 150 mg daily have been studied; at supra-therapeutic doses, the risk of rebound thrombocytopenia upon discontinuation may also be increased.
Take the tablet on an empty stomach, at least 2 hours before or 4 hours after eating. Swallow whole with water (not milk or calcium-fortified beverages). Wait at least 4 hours before or 2 hours after taking antacids, iron supplements, or mineral supplements. Do not crush, chew, or split the tablet.
What Are the Side Effects of Eltrombopag Teva GmbH?
Like all medicines, Eltrombopag Teva GmbH can cause side effects, although not everybody gets them. The side effect profile varies depending on the indication being treated (ITP, hepatitis C, or aplastic anemia), as the underlying conditions and concomitant therapies differ significantly. The following frequency categories are based on pooled clinical trial data and post-marketing surveillance reports.
Very Common
- Headache
- Nausea
- Diarrhea
- Elevated liver enzymes (ALT, AST)
- Upper respiratory tract infection
- Fatigue
Common
- Anemia
- Decreased appetite
- Insomnia or sleep disturbances
- Cough
- Abdominal pain and discomfort
- Vomiting
- Rash, pruritus (itching), or alopecia (hair loss)
- Musculoskeletal pain (back pain, myalgia, arthralgia)
- Paresthesia (tingling or numbness)
- Dry eye
- Elevated bilirubin
- Oropharyngeal pain (sore throat)
Uncommon
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Portal vein thrombosis (especially in patients with liver disease)
- Retinal vein occlusion
- Hepatotoxicity with jaundice
- Cataracts or lens opacities
- Bone marrow reticulin fiber increase
- Hyperbilirubinemia
- Peripheral edema
Rare
- Severe hepatotoxicity requiring treatment discontinuation
- Myocardial infarction or stroke (thrombotic events)
- Bone marrow fibrosis (collagen fibrosis)
- Severe skin reactions
- Nephrotoxicity
- Rebound severe thrombocytopenia upon discontinuation
Contact your doctor or go to the emergency department immediately if you experience: yellowing of the skin or eyes (jaundice), dark urine, unusual tiredness suggesting liver problems; sudden chest pain, shortness of breath, or leg swelling suggesting a blood clot; severe or worsening bleeding; new or worsening vision problems; or significant changes in stool color.
The hepatotoxicity risk warrants particular attention. In clinical trials across all indications, approximately 10-11% of patients developed ALT elevations ≥3 times the upper limit of normal. Most cases were asymptomatic and reversible upon dose reduction or discontinuation. However, severe cases with clinical hepatitis and jaundice have been reported, typically within the first few months of treatment. The mechanism of hepatotoxicity is not fully understood but may involve direct hepatocellular toxicity related to drug concentration in the liver, as eltrombopag undergoes significant hepatic uptake via OATP1B1.
Regarding thromboembolic events, the risk is inherently complex because thrombocytopenic patients may paradoxically develop thrombosis. This is especially relevant in patients with ITP who have other risk factors, and in patients with chronic liver disease who may develop portal vein thrombosis. In the EXTEND long-term ITP study, the incidence of thromboembolic events was approximately 4% with extended follow-up. Maintaining the lowest effective platelet count is critical for minimizing this risk.
How Should You Store Eltrombopag Teva GmbH?
Store Eltrombopag Teva GmbH film-coated tablets at a temperature not exceeding 30°C (86°F). Keep the tablets in the original blister packaging or bottle to protect from moisture and light. Do not transfer tablets to a different container unless it provides equivalent protection. The integrity of the film coating is important for protecting the active ingredient from degradation.
Keep this medicine out of the sight and reach of children. Even a single tablet could cause significant platelet elevation in a child, which may lead to serious complications. Store in a secure location. Do not use this medicine after the expiry date (EXP) stated on the carton and blister/bottle. The expiry date refers to the last day of that month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist about proper disposal of medicines you no longer use. Eltrombopag should be handled with care, and any unused tablets should be returned to a pharmacy for safe disposal in accordance with local environmental protection regulations. This is especially important because eltrombopag is a biologically active compound that should not enter the water supply.
What Does Eltrombopag Teva GmbH Contain?
The active substance in Eltrombopag Teva GmbH is eltrombopag, present as eltrombopag olamine (the diethanolamine salt). Each 25 mg film-coated tablet contains eltrombopag olamine equivalent to 25 mg of eltrombopag free acid. The olamine salt form was selected for its favorable physicochemical properties, including improved aqueous solubility compared to the free acid, which enhances oral bioavailability.
The tablet core typically contains excipients such as magnesium stearate (lubricant), mannitol (diluent), microcrystalline cellulose (filler and binder), povidone (binder), and sodium starch glycolate (disintegrant). These inactive ingredients serve essential pharmaceutical functions: ensuring uniform drug distribution throughout the tablet, facilitating tablet compression during manufacturing, and promoting rapid disintegration and dissolution in the gastrointestinal tract for consistent drug absorption.
The film coating contains ingredients such as hypromellose (hydroxypropyl methylcellulose), titanium dioxide (opacifier and colorant), macrogol/polyethylene glycol (plasticizer), and potentially iron oxide colorants depending on the tablet strength. The film coating serves multiple purposes: it protects the active ingredient from moisture and light, masks the taste of the drug substance, facilitates swallowing, and provides a distinctive appearance for identification. The coating does not affect the drug release profile, as eltrombopag is an immediate-release formulation.
The tablet has a characteristic appearance — typically a round or oval shape with specific markings for identification. Always check that the tablets match the description in the patient information leaflet supplied with your medicine. If the tablets look different or damaged, do not take them and consult your pharmacist.
Frequently Asked Questions About Eltrombopag Teva GmbH
Eltrombopag Teva GmbH is a thrombopoietin receptor agonist used to treat thrombocytopenia (low platelet count) in three main clinical settings: chronic immune thrombocytopenia (ITP) in adults who have not responded adequately to other treatments such as corticosteroids or immunoglobulins; thrombocytopenia in adults with chronic hepatitis C virus (HCV) infection who need antiviral therapy but cannot start due to low platelet counts; and severe aplastic anemia (SAA) in adults who have had insufficient response to immunosuppressive therapy. It works by stimulating the bone marrow to produce more platelets.
Eltrombopag typically begins to increase platelet counts within 1 to 2 weeks of starting treatment. However, the time to optimal platelet response varies between patients and depends on the underlying condition, starting platelet count, and dose. In clinical trials for ITP, most patients showed a measurable platelet response by week 2, with many achieving target levels (usually ≥50 × 109/L) within 2 to 4 weeks after dose optimization. Your doctor will monitor your platelet count regularly and make dose adjustments as needed to achieve and maintain the target range.
No, eltrombopag should be taken on an empty stomach, at least 2 hours before or 4 hours after meals. This is because polyvalent cations found in many foods — especially calcium in dairy products and calcium-fortified foods — chelate (bind to) eltrombopag and can reduce its absorption by up to 70%. Similarly, you should avoid taking antacids, iron supplements, or multivitamins within 4 hours of your eltrombopag dose. Take the tablet with water only.
The most serious potential side effects include hepatotoxicity (liver damage), which requires regular monitoring of liver function tests (ALT, AST, bilirubin); thromboembolic events such as deep vein thrombosis, pulmonary embolism, or portal vein thrombosis; and bone marrow reticulin fiber formation, which may rarely progress to myelofibrosis. Additionally, stopping eltrombopag may cause platelet counts to drop below pre-treatment levels, increasing bleeding risk. Signs that require immediate medical attention include yellowing of the skin or eyes, dark urine, sudden chest pain, shortness of breath, leg swelling, or unusual bleeding.
Yes, Eltrombopag Teva GmbH is a generic version of eltrombopag, which was originally developed and marketed by Novartis under the brand names Revolade (in the EU and other markets) and Promacta (in the United States). As a generic medicine approved through regulatory processes, it contains the same active ingredient (eltrombopag olamine) in the same dosage form and strength. It has been demonstrated to be bioequivalent to the reference product, meaning it is absorbed at the same rate and extent, ensuring comparable clinical efficacy and safety.
If you miss a dose, take it as soon as you remember on the same day, as long as you can still maintain the required fasting period (at least 2 hours before or 4 hours after food). Do not take two doses on the same day to make up for a missed dose. If it is already close to the time of your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Missing occasional doses is unlikely to have an immediate effect on platelet counts, but consistent adherence is important for maintaining stable platelet levels.
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). Summary of Product Characteristics: Eltrombopag. EMA/CHMP Assessment Report. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Promacta (eltrombopag) Prescribing Information. FDA Reference ID. Last revised 2024.
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966
- Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540-1550. doi:10.1056/NEJMoa1613878
- Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237-2247. doi:10.1056/NEJMoa071014
- Afdhal NH, Giannini EG, Vaez-Mohdavi F, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716-724. doi:10.1056/NEJMoa1110709
- World Health Organization. WHO Model List of Essential Medicines — 23rd list (2023). Geneva: WHO; 2023.
- British National Formulary (BNF). Eltrombopag. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
- Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527-2536. doi:10.1182/blood-2017-04-748707
- Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649-1658. doi:10.1016/S0140-6736(15)61107-2
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians with expertise in hematology, clinical pharmacology, and internal medicine.
Content prepared by clinical pharmacologists and hematology specialists following international guidelines (EMA, FDA, ASH, WHO) and the GRADE evidence framework.
Independently reviewed by the iMedic Medical Review Board. All medical claims verified against peer-reviewed literature and current prescribing information.
Evidence Level 1A based on systematic reviews, randomized controlled trials, and international clinical guidelines. No commercial funding or pharmaceutical sponsorship.
Content follows iMedic Editorial Standards. Updated regularly to reflect latest evidence. Conflicts of interest: none declared.